Anticorps Recombinant de lapin anti-VEGFR2/CD309

VEGFR2/CD309 Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

FC

Conjugaison

CoraLite®594 Fluorescent Dye

CloneNo.

230238B11

N° de cat : CL594-98009

Synonymes

KDR, VEGFR2, VEGFR2/KDR, Protein-tyrosine kinase receptor flk-1, FLK-1



Applications testées

Résultats positifs en cytométriecellules HUVEC,

Dilution recommandée

ApplicationDilution
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, check data in validation data gallery

Informations sur le produit

CL594-98009 cible VEGFR2/CD309 dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Protéine recombinante
Nom complet kinase insert domain receptor (a type III receptor tyrosine kinase)
Masse moléculaire calculée 152 kDa
Numéro d’acquisition GenBankNM_002253
Symbole du gène KDR
Identification du gène (NCBI) 3791
Conjugaison CoraLite®594 Fluorescent Dye
Excitation/Emission maxima wavelengths588 nm / 604 nm
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide and 0.5% BSA
Conditions de stockageStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

Informations générales

VEGFR2, also named as CD309, KDR and FLK1, is a receptor for VEGF or VEGFC. VEGFR2 which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGFR2 functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.

Protocole

Product Specific Protocols
FC protocol for CL594 VEGFR2/CD309 antibody CL594-98009Download protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}